Krystal Biotech

ISIN US5011471027

 | 

WKN A2JH2F

Market cap (in EUR)
7,736 m
Country
United States
Sector
Healthcare
Dividend yield
0.00%
 

Overview

Description

Krystal Biotech, Inc. operates as a biotechnology company, which engages in discovery, development, manufacturing, and commercialization of pharmaceutical products. It offers the product, VYJUVEK. The company was founded by Krish S. Krishnan and Suma M. Krishnan on April 15, 2016 and is headquartered in Pittsburgh, PA.
Show more Show less
Healthcare Biopharmaceuticals System-Specific Biopharmaceuticals United States

Financials

Key metrics

Market capitalisation, EUR 7,736 m
EPS, EUR 6.46
P/B ratio 7.0
P/E ratio 40.7
Dividend yield 0.00%

Income statement (2025)

Revenue, EUR 345 m
Net income, EUR 182 m
Profit margin 52.64%

What ETF is Krystal Biotech in?

There are 5 ETFs which contain Krystal Biotech. All of these ETFs are listed in the table below. The ETF with the largest weighting of Krystal Biotech is the iShares Nasdaq US Biotechnology UCITS ETF USD (Dist).
ETF Weight Investment focus Fund size (in m EUR)
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) 0.61%
Equity
United States
Health Care
Biotech
46
iShares S&P SmallCap 600 UCITS ETF 0.44%
Equity
United States
Small Cap
2,523
Vanguard ESG Global All Cap UCITS ETF (USD) Distributing 0.01%
Equity
World
Social/Environmental
531
Vanguard ESG North America All Cap UCITS ETF (USD) Distributing 0.01%
Equity
North America
Social/Environmental
26
JPMorgan BetaBuilders US Small Cap Equity UCITS ETF USD (dist) 0.11%
Equity
United States
Small Cap
210
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH.

Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.